LTRN Q1 2024 Earnings — Lantern Pharma Inc. Revenue & Financial Results | Market Cap Arena

LTRNLantern Pharma Inc.

$31M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$6M

Net Income

-$5M

EPS (Diluted)

$-0.51

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$134,057

Balance Sheet

Total Assets

$40M

Total Liabilities

$4M

Stockholders' Equity

$36M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$6M	-$4M	-33.7%
Net Income	-$5M	-$4M	-40.7%